BACKGROUND: The only potentially curative approach for pancreatic cancer is surgical resection, but this technically challenging procedure carries risks for postoperative morbidities and mortality. This study of a large, contemporary national database illustrates incidences of, and risk factors for, post-procedural mortality, prolonged hospital stay, and 30-day readmission. METHODS: From the National Cancer Database (NCDB), stage I-III pancreatic adenocarcinomas were identified [2004-2015]. Surgical techniques included pancreaticoduodenectomy, partial pancreatectomy (selective removal of the pancreatic body/tail), total pancreatectomy (removal of the entire pancreas) with or without subtotal resection of the duodenum and/or stomach, and extended pancreatectomy. Predictors of 30/90-day post-operative mortality, 30-day readmission rates, and prolonged hospital stay (>17 days per receiver operating curve analysis) were identified via multivariable logistic regression. RESULTS: Overall, 24,798 patients were analyzed (median age of 66). The majority of cases were T3 (47%), N0 (65%), pancreatic head lesions (83%), and treated with pancreaticoduodenectomy (57%). Only 16% received neoadjuvant therapy. Overall unadjusted risk of 30- and 90-day mortality ranged from 1.3-2.5% and 4.1-7.1%, respectively, depending on extent of surgery. Independent predictors of 30-/90-day mortality included preoperative therapy, increasing age, higher comorbidity score, lower income, case volume, and more extensive surgery. Similar findings were demonstrated regarding prolonged hospital stay and 30-day readmission. Age ≥70 was most associated with 30-day mortality, whereas age ≥60 was most associated with 90-day mortality and prolonged hospital stay. CONCLUSIONS: Quantitation of incidences and risk factors for postoperative outcomes following resection for pancreatic cancer is essential for judicious patient selection and shared decision-making between providers and patients. 2019 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: The only potentially curative approach for pancreatic cancer is surgical resection, but this technically challenging procedure carries risks for postoperative morbidities and mortality. This study of a large, contemporary national database illustrates incidences of, and risk factors for, post-procedural mortality, prolonged hospital stay, and 30-day readmission. METHODS: From the National Cancer Database (NCDB), stage I-III pancreatic adenocarcinomas were identified [2004-2015]. Surgical techniques included pancreaticoduodenectomy, partial pancreatectomy (selective removal of the pancreatic body/tail), total pancreatectomy (removal of the entire pancreas) with or without subtotal resection of the duodenum and/or stomach, and extended pancreatectomy. Predictors of 30/90-day post-operative mortality, 30-day readmission rates, and prolonged hospital stay (>17 days per receiver operating curve analysis) were identified via multivariable logistic regression. RESULTS: Overall, 24,798 patients were analyzed (median age of 66). The majority of cases were T3 (47%), N0 (65%), pancreatic head lesions (83%), and treated with pancreaticoduodenectomy (57%). Only 16% received neoadjuvant therapy. Overall unadjusted risk of 30- and 90-day mortality ranged from 1.3-2.5% and 4.1-7.1%, respectively, depending on extent of surgery. Independent predictors of 30-/90-day mortality included preoperative therapy, increasing age, higher comorbidity score, lower income, case volume, and more extensive surgery. Similar findings were demonstrated regarding prolonged hospital stay and 30-day readmission. Age ≥70 was most associated with 30-day mortality, whereas age ≥60 was most associated with 90-day mortality and prolonged hospital stay. CONCLUSIONS: Quantitation of incidences and risk factors for postoperative outcomes following resection for pancreatic cancer is essential for judicious patient selection and shared decision-making between providers and patients. 2019 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Amer H Zureikat; Lauren M Postlewait; Yuan Liu; Theresa W Gillespie; Sharon M Weber; Daniel E Abbott; Syed A Ahmad; Shishir K Maithel; Melissa E Hogg; Mazen Zenati; Clifford S Cho; Ahmed Salem; Brent Xia; Jennifer Steve; Trang K Nguyen; Hari B Keshava; Sricharan Chalikonda; R Matthew Walsh; Mark S Talamonti; Susan J Stocker; David J Bentrem; Stephanie Lumpkin; Hong J Kim; Herbert J Zeh; David A Kooby Journal: Ann Surg Date: 2016-10 Impact factor: 12.969
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti Journal: Ann Surg Date: 2007-08 Impact factor: 12.969
Authors: Richard S Swanson; Christopher M Pezzi; Katherine Mallin; Ashley M Loomis; David P Winchester Journal: Ann Surg Oncol Date: 2014-09-05 Impact factor: 5.344
Authors: William A Stokes; Michael R Bronsert; Robert A Meguid; Matthew G Blum; Bernard L Jones; Matthew Koshy; David J Sher; Alexander V Louie; David A Palma; Suresh Senan; Laurie E Gaspar; Brian D Kavanagh; Chad G Rusthoven Journal: J Clin Oncol Date: 2018-01-18 Impact factor: 44.544
Authors: Robert E Glasgow; Heidi H Jackson; Leigh Neumayer; Tracy L Schifftner; Shukri F Khuri; William G Henderson; Sean J Mulvihill Journal: J Am Coll Surg Date: 2007-06 Impact factor: 6.113